Full Text View
Tabular View
No Study Results Posted
Related Studies
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma
This study has been completed.
First Received: October 21, 2004   Last Updated: November 17, 2009   History of Changes
Sponsor: Medarex
Information provided by: Medarex
ClinicalTrials.gov Identifier: NCT00094653
  Purpose

The purpose of this study is to determine the safety and efficacy of MDX-010 (anti-CTLA4) in combination with MDX-1379 in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing IL-2, dacarbazine, and/or temozolomide, have 1) relapsed following an objective response (PR/CR); 2) failed to demonstrate an objective response (PR/CR); or 3) could not tolerate such a regimen due to unacceptable toxicity. Patients will be randomized into one of three groups, and will receive one of the following treatments: MDX-010 alone, MDX-1379 alone, or MDX-010 in combination with MDX-1379.


Condition Intervention Phase
Melanoma
Metastases
Drug: MDX-010 (anti-CTLA4) monoclonal antibody
Biological: MDX-1379 Melanoma Peptide Vaccine
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma

Resource links provided by NLM:


Further study details as provided by Medarex:

Primary Outcome Measures:
  • Best Objective Response Rate (BORR) [ Time Frame: BORR will be measure at 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: all patients will be followed until a mortality rate of 75% in vaccine arm is reached ] [ Designated as safety issue: No ]
  • Major durable response rate [ Time Frame: from baseline measurements through to patient completement ] [ Designated as safety issue: No ]
  • duration of response [ Time Frame: from confirmation of response to confirmation of progression ] [ Designated as safety issue: No ]
  • progression free survival [ Time Frame: measured from initial drug administration to time of progression ] [ Designated as safety issue: No ]
  • time to progression [ Time Frame: from time of initial drug administration to confirmed progression ] [ Designated as safety issue: No ]
  • health-related Quality of Life [ Time Frame: up to day 162 ] [ Designated as safety issue: No ]

Enrollment: 676
Study Start Date: September 2004
Study Completion Date: October 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Melanoma Peptide Vaccine (MDX-1379) + Placebo
Biological: MDX-1379 Melanoma Peptide Vaccine
2mL (2 subcutaneous injections of 1mL each, to each thigh), every 3 weeks for 4 doses.
2: Experimental
MDX-010 + MDX-1379 (Melanoma Peptide Vaccine)
Drug: MDX-010 (anti-CTLA4) monoclonal antibody
3mg/kg (iv infusion over 90 minutes), every 3 weeks for 4 doses
Biological: MDX-1379 Melanoma Peptide Vaccine
2mL (2 subcutaneous injections of 1mL each, to each thigh), every 3 weeks for 4 doses.
3: Active Comparator
MDX-010 + Placebo
Drug: MDX-010 (anti-CTLA4) monoclonal antibody
3mg/kg (iv infusion over 90 minutes), every 3 weeks for 4 doses

Detailed Description:

Melanoma accounts for approximately 5% of all skin cancers in the United States, but it accounts for about 75% of all skin cancer deaths. In 2004, the expected prevalence of melanoma is 627,252, with about 119,178 of these cases being Stage III or IV (metastatic melanoma). First line treatments for metastatic melanoma, usually IL-2, dacarbazine and/or temozolomide, are associated with significant toxicities. MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation. MDX-1379 is made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with malignant melanoma
  • Measurable unresectable Stage III or IV melanoma
  • HLA-A*0201 positive
  • Previous treatment with & failure/relapse/inability to tolerate IL-2, dacarbazine and/or temozolomide
  • At least 4 weeks since prior treatment
  • Negative pregnancy
  • Life expectancy greater than 4 months
  • ECOG performance of 0 or 1
  • Required lab values
  • HIV, HBV, HCV negative

Exclusion Criteria:

  • Prior malignancies which the patient has not been disease free for 5 years, except treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer
  • Ocular melanoma
  • Active, untreated CNS metastasis
  • Prior treatment with MDX-010 (anti-CTLA4) antibody
  • Prior treatment with any cancer therapeutic vaccine
  • Active autoimmune disease or history of autoimmune disease
  • Pregnancy or nursing
  • Hypersensitivity to Incomplete Freund's Adjuvant (IFA) (Montanide ISA-51)
  • Underlying medical conditions deemed hazardous if treated with study drug
  • Concomitant therapy with anti-melanoma drugs, chemotherapies, other investigational therapies, chronic use of systemic corticosteroids
  • Unable to provide informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00094653

  Hide Study Locations
Locations
United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
University Medical Center
Tucson, Arizona, United States, 85724
United States, California
Cancer Institute Medical Group, Inc
Santa Monica, California, United States, 90404
Cancer Institute Medical Group, Inc
Los Angeles, California, United States, 90025
San Diego Cancer Center
Vista, California, United States, 92081
San Diego Cancer Center
Encinitas, California, United States, 92024
North County Oncology Medical Clinical, Inc.
Oceanside, California, United States, 92056
Pacific Shores Medical Group
Long Beach, California, United States, 90813
City of Hope National Medical Center
Duarte, California, United States, 91010
City of Hope Medical Group
Pasadena, California, United States, 91105
Scripps Cancer Center
La Jolla, California, United States, 92037
La Jolla Hematology and Oncology Medical Group
La Jolla, California, United States, 92037
St. Mary's Medical Center - Northern California Melanoma Center
San Francisco, California, United States, 94109
University of California, San Diego
San Diego, California, United States, 92103
Moores UCSD Cancer Center
La Jolla, California, United States, 92093
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
United States, Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado, United States, 80304
Rocky Mountain Cancer Centers
Lakewood, Colorado, United States, 80228
Rocky Mountain Cancer Centers
Longmont, Colorado, United States, 80501
Rocky Mountain Cancer Centers
Lone Tree, Colorado, United States, 80124
University of Colorado Hospital
Denver, Colorado, United States, 80262
Rocky Mountain Cancer Centers
Denver, Colorado, United States, 80218
Rocky Mountain Cancer Centers
Aurora, Colorado, United States, 80012
Rocky Mountain Cancer Centers
Littleton, Colorado, United States, 80120
Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80010
Rocky Mountain Cancer Centers
Colorado Springs, Colorado, United States, 80909
University of Colorado Health Sciences Center
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University School of Medicine - Oncology Outpatient Clinic
New Haven, Connecticut, United States, 06520
United States, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida, United States, 33180
Mount Sinai Medical Center
Miami Beach, Florida, United States, 33140
Palm Beach Cancer Institute
West Palm Beach, Florida, United States, 33401
Shands Jacksonville
Jacksonville, Florida, United States, 32209
Palm Beach Cancer Institute
Wellington, Florida, United States, 33414
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
Memorial Regional Cancer Center
Hollywood, Florida, United States, 33021
University of Florida/Jacksonville Faculty Clinic
Jacksonville, Florida, United States, 32209
Palm Beach Cancer Institute
Palm Beach Gardens, Florida, United States, 33410
University of Miami Hospital & Clinics
Miami, Florida, United States, 33136
Jackson Memorial Hospital & Clinics
Miami, Florida, United States, 33136
M.D. Anderson Cancer Center Orlando
Orlando, Florida, United States, 32806
United States, Georgia
Emory University Hospital-Winship Cancer Institute
Atlanta, Georgia, United States, 30322
United States, Illinois
Decatur Memorial Hospital
Decatur, Illinois, United States, 62526
Cancer Care Specialists of Central IL
Effingham, Illinois, United States, 62401
Cancer Care Specialists of Central IL
Decatur, Illinois, United States, 62526
Cardinal Bernardin Cancer Center, Loyola Unv. Med. Ctr.
Maywood, Illinois, United States, 60153
United States, Indiana
Indiana Oncology Hematology Consultants North
Indianapolis, Indiana, United States, 46202
Indiana Oncology Hematology South
Indianapolis, Indiana, United States, 46237
Indiana Oncology Hematology Consutants of Noblesville
Noblesville, Indiana, United States, 46060
Center for Cancer Care at Goshen Health System
Goshen, Indiana, United States, 46526
American Health Network of IN, LLC
Indianapolis, Indiana, United States, 46237
United States, Kentucky
Norton Hospital
Louisville, Kentucky, United States, 40202
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202
University of Louisville Hospital
Louisville, Kentucky, United States, 40202
Central Baptist Hospital
Lexington, Kentucky, United States, 40503
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202
United States, Maryland
Franklin Square Hospital Center
Baltimore, Maryland, United States, 21237
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lutherville, Maryland, United States, 21093
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Brigham and Womens Hospital
Boston, Massachusetts, United States, 02115
Beth Isreal Dec Medical Center
Boston, Massachusetts, United States, 02115
United States, Michigan
Henry Ford Medical Center- West Bloomfield
West Bloomfield, Michigan, United States, 48322
Henry Ford Medical Center
Dearborn, Michigan, United States, 48126
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Minnesota
Hubert H Humphrey Cancer Center
Robbinsdale, Minnesota, United States, 55422
Humphrey Cancer Center
Coon Rapids, Minnesota, United States, 55433
Humphrey Cancer Center
Fridley, Minnesota, United States, 55432
United States, Mississippi
Family Cancer Center
Olive Branch, Mississippi, United States, 38654
United States, Missouri
Washington Unv. School of Med./ Siteman Cancer Center
St. Louis, Missouri, United States, 63110
St. Joseph Oncology, Inc
St. Joseph, Missouri, United States, 64507
Ellis Fischel Cancer Center
Columbia, Missouri, United States, 65203
Barnes Jewish Hospital
St. Louis, Missouri, United States, 63110
United States, New Jersey
Overlook Oncology Center
Summit, New Jersey, United States, 07901
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Hematology-Oncology Associates of Northern NJ, PA
Morristown, New Jersey, United States, 07962
The Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08901
United States, New Mexico
New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico, United States, 87109
United States, New York
Hematology-Oncology Associates of CNY
East Syracuse, New York, United States, 13057
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Columbia University Medical Center, Irving Center for Clinical Research
New York, New York, United States, 10032
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7050
United States, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
The Christ Hospital Cancer Center
Cincinnati, Ohio, United States, 45219
United States, Oregon
Providence Portland Medical Center
Portland, Oregon, United States, 97213
The Oregon Clinical
Portland, Oregon, United States, 97213
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States, 15232
Thomas Jefferson University Hosptital
Philadelphia, Pennsylvania, United States, 19107
Hillman Cancer Research Pavilion
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Cancer Centers of the Carolinas
Greenville, South Carolina, United States, 29615
Cancer Centers of the Carolinas
Spartanburg, South Carolina, United States, 29307
Cancer Centers of the Carolinas
Easley, South Carolina, United States, 29640
Cancer Centers of the Carolinas
Seneca, South Carolina, United States, 29672
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
The West Clinic
Memphis, Tennessee, United States, 38120
Family Cancer Center
Collierville, Tennessee, United States, 38017
Family Cancer Center
Memphis, Tennessee, United States, 38119
Family Cancer Center
Bartlett, Tennessee, United States, 38133
United States, Texas
Arlington Cancer Center
Arlington, Texas, United States, 76012
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, United States, 79410
Center for Oncology Research and Treatment
Dallas, Texas, United States, 75230
Center for Oncology Research and Treatment
Richardson, Texas, United States, 75080
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112-5550
United States, Vermont
Fletcher Allen Health Care
Burlington, Vermont, United States, 05405
Argentina
ISIS Clinica Especializada
Santa Fe, Argentina, S3000FFU
Hospital General de Agudos Carlos G. Durand
Ciudad de Buenos Aires, Argentina, C1405DCS
Hospital Privado de Cordoba S.A.
Cordoba, Argentina, X5016KEH
Instituto Alexander Fleming
Ciudad de Buenos Aires, Argentina, C1426DRB
Hospital Militar Central
Ciudad de Buenos Aires, Argentina, C1426BOS
Instituto de Oncologia Angel H. Roffo
Ciudad de Buenos Aires, Argentina, C1417DTB
Hospital Britanico de Buenos Aires
Ciudad de Buenos Aires, Argentina, C1280AEB
Hospital Municipal de Oncologia Maria Curie
Ciudad de Buenos Aires, Argentina, C1405BWU
Hospital Militar Central
Buenos Aires, Argentina
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Argentina
Hospital Privado Centro Medico de Cordoba S.A.
Cordoba, Argentina
ISIS Clinica Especializada
Santa Fe, Argentina
Argentina, Buenos Aires
Hospital Municipal de Oncoligia Maria Curie
Ciudad de Buenos Aires, Buenos Aires, Argentina
Argentina, Provincia de Buenos Aires
Instituto Medico Platense
La Plata, Provincia de Buenos Aires, Argentina, 1900
Belgium
Institut Jules Bordet
Brussels, Belgium, 1000
U.Z. Gent
Gent, Belgium, 9000
Universitair Ziekenhuis Gasthuisberg
Leuven, Belgium, 3000
Erasme Hospital
Brussels, Belgium, 1070
Cliniques Universitaires UCL de Mont-Godinne
Yvoir, Belgium, 5530
Erasme Hospital, Free Universtiy of Brussels
Brussels, Belgium, 1070
Brazil
Santo Andre Diagnosticos e Tratamentos Ltda.
Santo Andre-SP, Brazil, 09090-780
Hospital Sirio Labanes
Sao Paulo-SP, Brazil, 01308-050
Hospital Sao Lucas - PUCRS
Porto Alegre - Rs, Brazil, 90610-000
Hospital Araujo Jorge
Goiania - Go, Brazil, 74605-070
Fund. SOAD / HC de Porto Alegre
Porto Alegre - Rs, Brazil, 90035-003
HC-FMUSP
Sao Paulo - Sp, Brazil, 05403-000
Pro Onco Centro Tratemento Oncologico
Londrina - Pr, Brazil, 86050-190
Hospital de Cancer de Barretos - Fundacao Pio XII
Barretos - Sp, Brazil, 14784-400
Biocor - Hosp. de Doencas Cardiovasculares Ltda.
Belo Horizonte - Mg, Brazil, 34000-000
Fundacao Central Sul-Americana para o Desenvolvimento de Drogas Anticancer-SOAD
Porto Alegre, Brazil, 90035-003
Brazil, GO
Hospital Araujo Jorge da Associacoa de Combate ao Cancer em Goias
Goiania, GO, Brazil
Brazil, PR
Pro Onco Centro Tratamento Oncologico
Londrina, PR, Brazil
Brazil, RS
Hospital Sao Lucas da PUCRS
Porto Alegre, RS, Brazil
Brazil, SP
Fundacao Pio XII - Hospital de Cancer de Barretos
Barretos, SP, Brazil
Fundacoa Hospital Amaral Carvalho
Jau, SP, Brazil
Santo Andre Diagnosticos aTratamentos
Santo Andre, SP, Brazil
Sociedade Beneficante de Sennores - Hospital Sino Libante
Sao Paulo, SP, Brazil
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Manitoba
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Newfoundland and Labrador
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Ontario
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Cancer Centre of Southeastern Ontario at KGH
Kingston, Ontario, Canada, K7L 5P9
The Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Sir Mortimer B. Davis - Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Chile
Fundacion Arturo Lopez Perez
Santiago, Chile
Hospital Barros Luco
Santiago, Chile
Chile, Santiago
Clinica Davila
Recoleta, Santiago, Chile
Instituto Nacional del Cancer
Independencia, Santiago, Chile
Chile, Vina Del Mar
Clinica Renaca
Renaca, Vina Del Mar, Chile
France
Centre Leon Berard
Lyon, France, 69373 Cedex 08
Hopital Saint-Eloi
Montpellier, France, 34295 Cedex 5
Hotel Dieu
Nantes, France, 44093 Cedex 1
Centre-Hospitalier Universitaire de Saint-Etienne
Saint-Etienne, France, 42055 Cedex 2
Centre Eugene Marquis
Rennes, France, 35042 Cedex
Institut Gustave Roussy (IGR)
Villejuif, France, 94805 Cedex
Centre Oscar Lambret
Lille, France, 59020 Cedex
Hopital Sainte-Marguerite
Marseille, France, 13009
Hopital Saint-Louis
Paris, France, 75010 10
Centre Alexis Vautrin
Vandoeuvre Les Nancy, France, 54511 Cedex
Centre Antoine Lacassagne
Nice Cedex 2, France, 06189
Germany
Charite-Universitaetsmedizin Berlin, Campus Benjamin Franklin
Berlin, Germany, 12200
Universitaetsklinikum Wuerzburg
Wuerzburg, Germany, 97080
Universitaetsklinikum Tuebingen
Tuebingen, Germany, 72076
Universitaetsklinikum Essen
Essen, Germany, 45122
Universitaetsklinikum Heidelberg
Heidelburg, Germany, 69115
Klinikum Rechts der Isar / TU Muenchen
Muenchen, Germany, 81675
Charite Universitaets medizin Berlin
Berlin, Germany, 10117
Klinikum der Friedrich-Schiller-Universitaet Jena
Jena, Germany, 07740
Universitaetsklinikum Erlangen
Erlangen, Germany, 91052
Universitaetsklinikum Dusseldorf
Duesseldorf, Germany, 40225
Klinikum Augsburg
Augsburg, Germany, 86156
Klinikum Mannheim gGmbH
Mannheim, Germany, 68167
University of Mannheim
Mannheim, Germany
Germany, Essen
Klinik fur und Poliklinik fur Dermatologie, Venerologie und Allergologie
Hufelandstr. 55, Essen, Germany, 45122
Hungary
National Institute of Oncology
Budapest, Hungary, H-1122
Semmelweis Hospital
Miskolc, Hungary, H-3529
University of Szeged, Albert Szent-Gyorgyi Medical and Pharmaceutical Center
Szeged, Hungary, H-6720
University of Debrecen, Medical and Health Sciences Center
Debrecen, Hungary, H-4012
Netherlands
Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands, 1066 CX
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands, 6229 HX
Vrije Universiteit Medisch Centrum (VUMC)
Amsterdam, Netherlands, 1081 HV
South Africa
Mary Potter Oncology Centre
Pretoria, South Africa, 0181
GVI Oncology
Panorama, South Africa, 7500
Sandton Onocology Medical Research
Sandton, South Africa, 2199
Mary Potter Oncology Centre
Groenkloof, South Africa, 0181
Switzerland
Centre Hospitalier Universitaire Vaudois - CHUV
Lausanne, Switzerland, CH-1011
Dermatologische Klinik Universitatsspital Zurich
Zurich, Switzerland, 8091
Switzerland, Rue du Bugnon 46
Centre Hospitalier Universitaire Vaudois - CHUV
Lausanne, Rue du Bugnon 46, Switzerland, CH-1011
United Kingdom
Velindre Hospital
Cardiff, United Kingdom, CF14 2TL
Churchill Hospital
Oxford, United Kingdom, OX3 7LJ
Christie Hospital
Manchester, United Kingdom, M20 4BX
Weston Park Hospital
Sheffield, United Kingdom, S10 2SJ
Poole Hospital
Poole, United Kingdom, BH15 2JB
Southampton General
Southampton, United Kingdom, SO16 6YD
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Ninewells Hospital
Dundee, United Kingdom, DD1 9SY
Weston Park Hospital
Sheffield, United Kingdom, S10 2SJ
United Kingdom, Surry
St. Luke's Cancer Center, The Royal Surrey County Hospital
Guildford, Surry, United Kingdom, GU2 7XX
Sponsors and Collaborators
Medarex
Investigators
Study Director: Medarex Medical Monitor Medarex
  More Information

No publications provided

Responsible Party: Medarex, Inc. ( Medarex Medical Monitor )
Study ID Numbers: MDX010-20
Study First Received: October 21, 2004
Last Updated: November 17, 2009
ClinicalTrials.gov Identifier: NCT00094653     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Medarex:
melanoma
metastatic melanoma
skin cancer

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs
Neoplasms, Nerve Tissue
Pharmacologic Actions
Melanoma
Neuroendocrine Tumors
Antibodies, Monoclonal
Neuroectodermal Tumors
Neoplasms
Neoplastic Processes
Antibodies
Pathologic Processes
Neoplasms, Germ Cell and Embryonal
Neoplasm Metastasis
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 27, 2009